To evaluate the healthcare cost for the management of diabetes along with other co-morbidities condition. METHODS: A cross-sectional study was conducted in the Community setup of Warangal, India for a period of three months. Only the educated Diabetic patients with other comorbidities were enrolled in the study. The data collected were cost of medications, lab tests, consultation fee, transportation cost. The average total healthcare cost was calculated based on the previous two months expenses of each patient. RESULTS: A total of 100 patients were evaluated in the study period. Out of 100 patients, majorities were in the age group of 41-61 yrs 66 (66%) and also found to be higher in men 63 (63%) than in women 37 (37%). Most of the patients were diabetes with hypertension, dyslipidemia. The average cost of medications per patient Rs. 1540 (72.81%), the average laboratory cost per patient Rs. 350 (16.55%), the average doctors consultation fee per patient Rs.175 (8.27%), the average transportation charges per patient Rs.50 (2.36%). The most common drugs prescribed in the study were Metformin, Glibenclamide, Gliclazide, Insulin, Ramipril, Amlodipine, Telmisartan, Metoprolol, Hydrochlorothiazide, Furosemide, Atorvastatin and Aspirin. The most common laboratory test includes FBS/PPBS/RBS/HbA1C, lipid profiles, urine analysis, Hb, Electrolytes and Sr.Creatinine. The average total healthcare cost for two months was found to be Rs.2115 per patient. CONCLUSIONS: In summary, this is the first Indian healthcare cost study conducted in the community setup. Diabetes imposes an enormous economic burden on the healthcare system worldwide. This burden will continue to increase in the next two decades. More prevention efforts and resources are required to reduce this burden and to provide basic diabetes care in the low-and middle-income countries. ) and if necessary, the prescription of a recommended class among angiotensin converting enzyme (ACE)-inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, calcium channel blockers (CCB) and thiazide diuretics. The objective of this study was to assess, for different patient's profiles, the cost-effectiveness of the recommended antihypertensive classes in France. METHODS: A cohort of newly treated patients entered a Markov model, using 1-month cycles in the first year, 1-year cycles until 10 years then lifetime extrapolation of costs and benefits. The cohort was characterized by its cardiovascular risk, evaluated via the France-specific Framingham equation. The risk reductions per class versus placebo were taken from the most recent meta-analyses. The probability to switch from monotherapy to bitherapy and tritherapy was depending on the achieved SBP (target 140mmHg) and the class-specific persistence. National health care databases provided persistence and costs data. Discount rate was 4% (costs and life-years). RESULTS: In low-risk patients (65-year-old female, SBP 150mmHg), incremental cost-effectiveness vs. placebo ranged from 101€/lifeyear gained (ACE-inhibitors followed by ACE-inhibitors/thiazides) to 7,722€/lifeyear gained (beta-blockers followed by beta-blockers/CCB). Savings and extra benefits vs. placebo were obtained in high-risk patients (74-year-old diabetic male, smokers, SBP 180mmHg): up to 0.57 life-years gained with total costs reduced from 17,630€ to 15,403€ (ACE-inhibitors followed by ACE-inhibitors/CCB, least expensive sequence) and 15,953€ (beta-blockers followed by beta-blockers/ARBs, most expensive sequence). The classes ranking was influenced by the persistence and diabetes incidence. The differences were significant vs. placebo but not between the classes, as per probabilistic sensitivity analysis. CONCLUSIONS: This lifetime model suggests that all recommended anti-hypertensive drugs in France are very cost-effective versus placebo, and, in higher-risk patients, are even cost-saving with savings comparable among the classes. 
PCV46 ASSESSING THE COST-EFFECTIVENESS OF THE RECOMMENDED ANTIHYPERTENSIVE DRUG CLASSES IN FRANCE USING A LIFETIME MARKOV MODEL

OBJECTIVES:
The management of arterial hypertension in France starts with an evaluation of the patient's cardiovascular risk (function of age, sex, cholesterol level, systolic blood pressure [SBP] ) and if necessary, the prescription of a recommended class among angiotensin converting enzyme (ACE)-inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, calcium channel blockers (CCB) and thiazide diuretics. The objective of this study was to assess, for different patient's profiles, the cost-effectiveness of the recommended antihypertensive classes in France. METHODS: A cohort of newly treated patients entered a Markov model, using 1-month cycles in the first year, 1-year cycles until 10 years then lifetime extrapolation of costs and benefits. The cohort was characterized by its cardiovascular risk, evaluated via the France-specific Framingham equation. The risk reductions per class versus placebo were taken from the most recent meta-analyses. The probability to switch from monotherapy to bitherapy and tritherapy was depending on the achieved SBP (target 140mmHg) and the class-specific persistence. National health care databases provided persistence and costs data. Discount rate was 4% (costs and life-years). RESULTS: In low-risk patients (65-year-old female, SBP 150mmHg), incremental cost-effectiveness vs. placebo ranged from 101€/lifeyear gained (ACE-inhibitors followed by ACE-inhibitors/thiazides) to 7,722€/lifeyear gained (beta-blockers followed by beta-blockers/CCB). Savings and extra benefits vs. placebo were obtained in high-risk patients (74-year-old diabetic male, smokers, SBP 180mmHg): up to 0.57 life-years gained with total costs reduced from 17,630€ to 15,403€ (ACE-inhibitors followed by ACE-inhibitors/CCB, least expensive sequence) and 15,953€ (beta-blockers followed by beta-blockers/ARBs, most expensive sequence). The classes ranking was influenced by the persistence and diabetes incidence. The differences were significant vs. placebo but not between the classes, as per probabilistic sensitivity analysis. CONCLUSIONS: This lifetime model suggests that all recommended anti-hypertensive drugs in France are very cost-effective versus placebo, and, in higher-risk patients, are even cost-saving with savings comparable among the classes. 
PCV47 ECONOMIC ANALYSIS OF TREATMENTS FOR PULMONARY ARTERIAL HYPERTENSION FROM THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE
PCV48 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE VERSUS ACETYLSALICILIC ACID FOR STROKE PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION UNDER THE PRIVATE AND PUBLIC HEALTH CARE SYSTEM IN BRAZIL
OBJECTIVES:
To compare costs and effectiveness of dabigatran etexilate (DAB) versus acetylsalicilic acid (ASA) in patients with Non-Valvular Atrial Fibrillation (NVAF) from a private and public health care system perspective in Brazil. METHODS: A Markov model was built to compare DAB versus ASA to derive incremental cost effectiveness ratio (ICER) of DAB based on a mixed treatment comparison and a modified Delphi panel with Brazilian experts (local clinical practice pattern on the management of NVAF patients). The model estimated the number of ischaemic and haemorrhagic strokes, systemic embolisms, intracranial hemorrhages, transient ischaemic attacks, extracranial hemorrhages, minor bleeds and acute myocardial infarctions associated with the respective treatments. To each clinical event costs, disabilities and/or reduction in quality of life, and risk of death were assigned. Only direct medical costs were considered and a discount rate of 5% was assumed, according to Brazilian HTA guidelines. A probabilistic sensitivity analysis was designed to assess uncertainty. RESULTS: Under both, the private and public perspective, DAB was associated with additional 0.31 life years gained (LY), additional 0.60 QALYs and demonstrated a lower incidence of intracranial events versus ASP, resulting in a lower event costs (-R$ 1,057.84 and -R$ 3,006.07) and follow up costs. The ICER for DAB versus ASA was R$ 38,511.06/LY and R$ 31,379.80/ QALY from the public perspective and DAB was dominant from the private perspective. Sensitivity analyses confirmed the cost-effectiveness of DAB. CONCLUSIONS: Findings suggest that DAB can be cost-effective for stroke prevention when used instead of ASA in NVAF patients in Brazil, given that DAB was dominant in the private sector and ICERS were below the threshold of other technologies reimbursed in the public health care sector. 
PCV49 COST-EFFECTIVENESS OF CARDIAC REHABILITATION PROGRAM ON PATIENT MEDICATION ADHERENCE AND HOSPITALIZATION IN MEDICAID POPULATION WITH ACUTE MYOCARDIAL INFARCTION
OBJECTIVES:
Although medication advice is a key component in cardiac rehabilitation (CR) program, little is known about its effectiveness on patient medication use behaviors. This project aimed to assess the cost-effectiveness of CR program on patient adherence to cardiac medication and the number of hospitalization avoided. METHODS: Using MarketScan® Medicaid database, patients with acute myocardial infarction (AMI) were targeted. By using propensity scores, 471 patients receiving CR programs during 2003-2007 were 1:1 matched with 471 controls (without CR) on patient demographics, comorbidities and healthcare costs before the CR started. The economic perspective was that of third-payer sector so only direct medical costs were included (costs attributed to CR program and the use of cardiac specific medical services and medications). Main outcomes were patient adherence to cardiac medication measured by Medication Possession Ratio and the number of cardiac related hospitalization. The cardiac medications studied were ␤1 selective-blockers, angiotensin converting enzyme inhibitors and angiotensin receptor blockers. The outcomes were estimated every 4 months during 1-year follow-up. Cost-effectiveness of CR program was determined by the incremental cost-A120 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
